Chemo-Free hope: new drug duo targets tough lung cancer
NCT ID NCT06865339
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial is testing whether combining two immunotherapy drugs (cemiplimab and fianlimab) with radiation can shrink tumors in people with locally advanced non-small cell lung cancer who haven't had treatment yet. The study will enroll 76 participants and measure how well the tumors respond using PET scans. The goal is to find a more effective, chemotherapy-free option for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cemiplimab and fianlimab (immunotherapy drugs) plus radiation
What this could lead to
If successful, this could offer a chemotherapy-free treatment option for locally advanced lung cancer, potentially improving response rates and long-term outcomes.
What could go wrong
This is an early Phase 2 trial with only 76 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like lung inflammation or colitis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Einstein Comprehensive Cancer Center (MECCC)
RECRUITINGThe Bronx, New York, 10461, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••